Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications

Q Zhong, X Xiao, Y Qiu, Z Xu, C Chen, B Chong… - MedComm, 2023 - Wiley Online Library
Protein posttranslational modifications (PTMs) refer to the breaking or generation of covalent
bonds on the backbones or amino acid side chains of proteins and expand the diversity of …

Metabolism and epigenetic interplay in cancer: regulation and putative therapeutic targets

V Miranda-Gonçalves, A Lameirinhas… - Frontiers in …, 2018 - frontiersin.org
Alterations in the epigenome and metabolism affect molecular rewiring of cancer cells
facilitating cancer development and progression. Modulation of histone and DNA …

[HTML][HTML] Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway

C Sun, S Li, F Zhang, Y Xi, L Wang, Y Bi, D Li - Oncotarget, 2016 - ncbi.nlm.nih.gov
Recently, the long non-coding RNA (lncRNA) NEAT1 has been identified as an oncogenic
gene in multiple cancer types and elevated expression of NEAT1 was tightly linked to …

The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: a narrative review

HS Rugo, I Jacobs, S Sharma, F Scappaticci… - Advances in …, 2020 - Springer
Epigenetic processes are essential for normal development and the maintenance of tissue-
specific gene expression in mammals. Changes in gene expression and malignant cellular …

[HTML][HTML] Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development

C Sun, C Huang, S Li, C Yang, Y Xi, L Wang, F Zhang… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Abstract Hsa-miRNA-326 (miR-326) has recently been discovered having anticancer
efficacy in different organs. However, the role of miR-326 on non-small cell lung cancer …

SMYD3: an oncogenic driver targeting epigenetic regulation and signaling pathways

C Bottino, A Peserico, C Simone, G Caretti - Cancers, 2020 - mdpi.com
SMYD3 is a member of the SMYD lysine methylase family and plays an important role in the
methylation of various histone and non-histone targets. Aberrant SMYD3 expression …

[HTML][HTML] Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1

CC Sun, SJ Li, DJ Li - Oncotarget, 2016 - ncbi.nlm.nih.gov
Abstract Hsa-miRNA-134 (miR-134) has recently been discovered to have anticancer
efficacy in different organs. However, the role of miR-134 on non-small cell lung cancer …

Epigenetic modulators as therapeutic targets in prostate cancer

I Graça, E Pereira-Silva, R Henrique, G Packham… - Clinical …, 2016 - Springer
Prostate cancer is one of the most common non-cutaneous malignancies among men
worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or …

Epigenetic mechanisms underlying prostate cancer radioresistance

C Macedo-Silva, R Benedetti, F Ciardiello… - Clinical …, 2021 - Springer
Radiotherapy (RT) is one of the mainstay treatments for prostate cancer (PCa), a highly
prevalent neoplasm among males worldwide. About 30% of newly diagnosed PCa patients …

H3K9me3, H3K36me3, and H4K20me3 expression correlates with patient outcome in esophageal squamous cell carcinoma as epigenetic markers

M Zhou, Y Li, S Lin, Y Chen, Y Qian, Z Zhao… - Digestive diseases and …, 2019 - Springer
Background Histone methylation, as an essential pattern of posttranslational modifications,
contributes to multiple cancer-related biological processes. Dysregulation of histone …